GPCR Activation and Signaling Targeting biased signaling by PAR1: Function and molecular mechanism of

Mark your calendars for the following events: September 22- TOMORROW: Attend this Friday's Dr.

Mark your calendars for these important events: September 22: Save the date for the Dr.

Be sure to mark your calendars and secure your spot for this extraordinary learning opportunity!

Before you do so, mark your calendars and join us for the Dr.

Mark your calendars and make sure to enroll before the deadline!

GPCR Ecosystem contents and perks Go to Dr. G-Protein Coupled Receptor Gpr-1 Is Important for the Growth and Nutritional Metabolism of an Invasive Bark

Targeting biased signaling by PAR1: function and molecular mechanism of parmodulins.

Find speaker details on the Live Talks page and mark your calendar HERE. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways Spliceosome mutations are associated

the response to nociception, i.e. the response of the nervous system to painful stimuli; the 1970s marked

GPCR University This week marks the beginning of our first Dr.GPCR University course, 'Applying Pharmacology our events, and get a complimentary Premium Membership with only 4 hours/monthly commitment on your part

Also, please mark your calendar for the next Dr. precision oncology pipeline announced by Exscientia Upcoming start-up ecosystem - leadXpro and InterAx part

GPCR Ecosystem contents and perks, including our forums, private groups, and all Ecosystem members Go application of optogenetically functionalized Drosophila dopamine receptors Targeting CB2R in astrocytes for Parkinson's

GPCR Ecosystem contents and perks, including our forums, private groups, and all Ecosystem members Go Meaningful Proof-of-Concept Data From Phase 2a Clinical Study Neurocrine opening two Phase 1 trials in oral Parkinson

GPCRs in Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's disease

A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's

the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's

beneficial pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson

neuropsychiatric diseases including Amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's

nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's

and D1R antagonism, kurarinone might be a potential compound that can alleviate clinical symptoms of Parkinson's